Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 2

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Gastrointestinal 2Breast 2Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × lobaplatin × Breast × Clear all
NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01483300 2012-01-24

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

Harbin Medical University

Phase 2 Unknown
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡